Download PDF

Register to download the report. Already a member?

 
 
Sign Up

Or

60275 1492790397HCLSReviewGreeceApril2017.pdf
Energy Boardroom

Gilead's Sovaldi sales through the roof already, analyst predicts at least $8B this year

07.03.2014 / Fierce Pharma

With a revolutionary approach to hepatitis C and a price tag of $84,000 per 12-week treatment course, analysts expected big sales from Gilead's Sovaldi. Some even forecast it would reach $9 billion or more by 2017, at which level it would surpass Pfizer's Lipitor to take the crown for biggest-selling drug of all time. But none expected the exponential growth the drug is posting right now.

LATEST ISSUE

DOWNLOAD

X
Download PDF

First Name:

Last Name:

Company:

Position:

Country:

Email: